Hereditary Transthyretin Amyloidosis Market Research Reveals Strong 8.9% CAGR Outlook Through 2030

The hereditary transthyretin amyloidosis market is poised for significant expansion in the coming years, driven by advancements in treatment options and a deeper understanding of the disease. Innovations in gene therapy and precision medicine are reshaping how this rare condition is managed, promising better patient outcomes and a growing interest in novel therapeutic approaches.

Projected Market Value and Growth Outlook for Hereditary Transthyretin Amyloidosis
The market for hereditary transthyretin amyloidosis is forecasted to reach a valuation of $2.28 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.9%. This upward trajectory is largely fueled by the development of next-generation gene therapies, increased funding for rare disease research, and the expanding use of precision medicine techniques. Additionally, advancements in CRISPR-based treatments and improved technologies for monitoring disease progression contribute to the market's promising growth. Emerging trends during this period include wider adoption of gene silencing therapies, the rise of RNAi-based treatment options, earlier diagnosis of cardiac and neurological symptoms, growth in oral therapies, and evolving strategies for long-term disease management.

The hereditary transthyretin amyloidosis market size has grown strongly in recent years. It will grow from $1.49 billion in 2025 to $1.62 billion in 2026 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing clinical recognition of attr amyloidosis, availability of tafamidis therapy, expansion of specialized neurology and cardiology centers, improved genetic testing for ttr mutations, rising patient registry programs.

Download a free sample of the hereditary transthyretin amyloidosis market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22003&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Companies Leading the Hereditary Transthyretin Amyloidosis Market
Several prominent players are actively involved in the hereditary transthyretin amyloidosis industry. These include Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Pfizer Inc., Eli Lilly and Company, Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb, Merck and Co Inc., Johnson and Johnson, AbbVie Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, and Amgen Inc.

A notable collaboration was announced in July 2023, when US-based Ionis Pharmaceuticals, which specializes in RNA-targeted drug discovery, partnered with UK-based AstraZeneca plc. Together, they aim to develop and market eplontersen for treating transthyretin amyloidosis (ATTR) in the United States. This partnership also plans to leverage AstraZeneca's strong international commercial presence to expand access to the treatment in Latin America and other global markets.

View the full hereditary transthyretin amyloidosis market report:
https://www.thebusinessresearchcompany.com/report/hereditary-transthyretin-amyloidosis-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Therapeutic Trends in the Global Hereditary Transthyretin Amyloidosis Market
Innovative treatments are at the forefront of the hereditary transthyretin amyloidosis market, with many companies focusing on RNA interference (RNAi) therapeutics designed to silence the production of the harmful transthyretin (TTR) protein. These therapies work by targeting specific genes responsible for the disease, offering a promising approach to managing symptoms and slowing progression.

For example, in October 2024, Alnylam Pharmaceuticals submitted a supplemental new drug application to the US FDA for Vutrisiran (AMVUTTRA), intended to treat transthyretin amyloidosis with cardiomyopathy. This RNAi therapeutic emphasizes a patient-friendly subcutaneous dosing regimen, which could transform treatment by providing a more convenient alternative to traditional intravenous administration.

Detailed Market Segmentation of the Hereditary Transthyretin Amyloidosis Industry
This report categorizes the hereditary transthyretin amyloidosis market across several segments:

1) Type: Oral, Subcutaneous Injection, Other Types
2) Drug Class: RNAi Agents (such as Patisiran), Small Interfering RNAs (siRNAs) like Vutrisiran
3) Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) Application: Hospitals, Clinics, and Other healthcare settings

Further breakdowns include:
- Oral treatments such as Tafamidis and experimental oral therapies
- Subcutaneous injections including Inotersen and Vutrisiran
- Other forms covering intravenous therapies, gene silencing approaches, and CRISPR-based treatments

This comprehensive segmentation sheds light on the diverse therapeutic options and delivery methods shaping the future of treatment for hereditary transthyretin amyloidosis.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.